Pfizer bagged a coveted first-line maintenance approval for Tukysa. In combination with HER2 antibody drugs, the treatment ...
Eli Lilly’s Jaypirca, the first noncovalent BTK inhibitor, has won FDA approval for the first-line treatment of chronic ...
Chronic lymphocytic leukemia (CLL), the most common leukemia of adults in Western countries, is standing at a genuine ...
Today's focus is on a new combination therapy for renal cell carcinoma approved by the US FDA on September 24, 2026. A drug ...
A four-tier algorithm for BMI ≥30 prioritizes semaglutide or tirzepatide, followed by phentermine–topiramate, liraglutide, then naltrexone–bupropion, reflecting graded certainty and comparative ...
Health and Me on MSN
FDA approves targeted cancer drug as first-line treatment for CLL that cuts progression risk by 80%
The US Food and Drug Administration (FDA) recently approved pirtobrutinib for people with previously untreated chronic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results